Bhavana Pothuri, MD, discusses the importance of obtaining patient-reported outcomes in ovarian cancer.
Bhavana Pothuri, MD, professor, Department of Obstetrics and Gynecology, NYU School of Medicine, director of gynecologic oncology clinical trials, NYU Langone Health’s Perlmutter Cancer Center, discusses the importance of obtaining patient-reported outcomes (PROs) in ovarian cancer.
At part of the 2020 SGO Annual Meeting virtual platform, a PROs analysis from the phase III PRIMA trial (ENGOT-OV26/GOG-3012) revealed that health-related quality-of-life (QOL) scores were similar for patients who received niraparib (Zejula) as frontline maintenance therapy compared with placebo.
PROs are critically important in understanding the impact of an investigational treatment on patients’ QOL, says Pothuri. Additionally, PROs can influence FDA regulations and guide treatment decisions in the clinic.
From a patient perspective, PROs also allow individuals to share their experience with a novel regimen, concludes Pothuri.